目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T40809 | |||
2α-Methyl androsterone is an anabolic androgenic steroid metabolite of mesterolone and drostanolone. | |||
T81662 | Androgen Receptor | ||
N-Nitrosodicyclohexylamine (NDCHA) 是一种N-亚硝基化合物,具有抗雄激素活性。它通过与雄激素受体 (AR) 竞争性结合来抑制 5α-二氢睾酮的作用,并能降低 AR 蛋白水平。 | |||
T73671 | |||
7β-Hydroxy-epi-androsterone (7β-Hydroxy-EpiA) 是一种与ERβ结合的内源性雄激素衍生物,具有抗炎和神经保护特性。该化合物来源于dehydroepiandrosterone。 | |||
TN4604 | BCL HSP NF-κB ROS Caspase STAT | ||
Myricanone has antioxidant, and anticancer activities, it has apoptosis-promoting ability by triggering caspase activation, and suppression of cell proliferation by down-regulation of NF-κB and STAT3 signalling cascades. Myricanone shows in vitro testost | |||
T21668 | |||
Finasteride (MK-906) acetate 是一种高效的5α-还原酶 (5α-reductase) 竞争性抑制剂,其对 II 型 5α-还原酶的IC50值仅为 4.2 nM,其对该型酶的亲和力是对 I 型酶亲和力的约100倍。因此,Finasteride acetate 主要在良性前列腺增生症 (BPH) 和雄激素性脱发研究领域中应用。 | |||
T61029 | |||
TP0427736 hydrochloride 可用于雄激素性脱发 (AGA) 研究。TP0427736 hydrochloride 可抑制由 TGF-β1 诱导的 A549 细胞中 Smad2/3 的磷酸化,IC50值为 8.68 nM。它也是ALK5激酶的有效抑制剂,IC50值为 2.72 nM,比对 ALK3 836 nM 的抑制作用高 300 倍。 | |||
T41331 | |||
Cyprodinil 是一种苯胺嘧啶广谱杀菌剂,可抑制植物病原真菌蛋氨酸的生物合成。Cyprodinil 抑制B. cinerea,P. herpotrichoides,H. oryzae 的菌丝体细胞在无氨基酸的培养基上生长,IC50s 分别为 0.44,4.8,0.03 μM。在没有 AR 激动剂 DHT 的情况下,Cyprodinil 充当雄激素受体 (AR) 激动剂 (EC50=1.91 μM),并抑制 DHT 的雄激素作用 (IC50=15.1 μM)。 | |||
T71142 | |||
Tebuconazole-d9 is intended for use as an internal standard for the quantification of tebuconazole by GC- or LC-MS. Tebuconazole is a triazole fungicide that is active against both seed and foliar fungi. It inhibits 14α-demethylase isolated from U. maydis and S. bicolor with IC50 values of 0.05 and 0.16 nM, respectively. It inhibits the androgenic effect of the androgen receptor agonist DHT (IC20 = 2.89 µM) and is cytotoxic (EC20 = 38.9 µM) in an MDA-kb2 assay. Tebuconazole (50 and 100 mg/kg per day) administered during gestation reduces testosterone levels and increases testicular levels of progesterone and 17α-hydroxyprogesterone in male rat fetuses. It has a feminizing effect on male pups and a virializing effect on female pups. When administered to rats gestationally through postnatal day 42, tebuconazole (20 and 60 mg/kg per day) leads to cell death of pyramidal cells in the CA3-4 region of the hippocampus and layer V of the cortex concomitant with impairment in learning...... |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02672 | Prostatic Acid Phosphatase Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Prostatic acid phosphatase (PAP, or ACPP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. As a non-specific phosphomonoesterase, Prostatic acid phosphatase is synthesized and secreted into seminal plasma under androgenic control. The enzyme is a dimer of molecular weight around 100 kDa. Prostatic acid phosphatase is a clinically important protein for its relevance as a biomarker of prostate carcinoma. Furthermore, it has a potential role in fertilization. The major action of PAP is to dephosphorylate macromolecules with the help of catalytic residues (His(12) and Asp(258)) that are located in the cleft between two domains. Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosine phosphatase, is proposed to function as a negative growth regulator of prostate cancer (PCa) cells in part through its dephosphorylation of ErbB-2. cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Injection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. This enzyme exhibits ecto-5'-nucleotidase activity, is widely distributed, and implicated in the formation of chronic pain. Additionally, PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
|
|||||
TMPY-02155 | Prostatic Acid Phosphatase Protein, Human, Recombinant (His) | Human | HEK293 | ||
Prostatic acid phosphatase (PAP, or ACPP), also known as prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. As a non-specific phosphomonoesterase, Prostatic acid phosphatase is synthesized and secreted into seminal plasma under androgenic control. The enzyme is a dimer of molecular weight around 100 kDa. Prostatic acid phosphatase is a clinically important protein for its relevance as a biomarker of prostate carcinoma. Furthermore, it has a potential role in fertilization. The major action of PAP is to dephosphorylate macromolecules with the help of catalytic residues (His(12) and Asp(258)) that are located in the cleft between two domains. Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosine phosphatase, is proposed to function as a negative growth regulator of prostate cancer (PCa) cells in part through its dephosphorylation of ErbB-2. cPAcP functions as a neutral protein tyrosine phosphatase (PTP) in prostate cancer cells and dephosphorylates HER-2/ErbB-2/Neu (HER-2: human epidermal growth factor receptor-2) at the phosphotyrosine (p-Tyr) residues. Injection of the secretory isoform of PAP has potent antinociceptive effects in mouse models of chronic pain. This enzyme exhibits ecto-5'-nucleotidase activity, is widely distributed, and implicated in the formation of chronic pain. Additionally, PAP could be a target molecule in specific immunotherapy for patients with nonprostate adenocarcinomas including colon and gastric cancers.
|